Fortunately, the data is strong enough to be believable, even given the caveats. Of 58 patients who had been treated for at least 12 weeks as of the last data release, 12 of them had Dravet syndrome, a type of childhood-onset epilepsy, and there were 12 patients who had drop seizures, which are associated with another type of childhood-onset epilepsy called Lennox-Gastaut syndrome.
Dravet syndrome patients saw their convulsive seizure frequency drop by 56% over 12 weeks of treatment compared to a four week observation period before the treatment started. Patients with drop seizures saw an equally impressive 52% reduction in seizures. Those two groups are important because they’re the ones with syndromes that GW Pharmaceuticals plans to run clinical trials on.
The first part of a phase 2/3 Dravet syndrome trial to determine the best dose was scheduled to conclude last month, and GW Pharmaceuticals expects to start the phase 3 portion of the trial and a second phase 3 trial in Dravet syndrome this quarter. There are also plans to start two additional phase 3 trials in Lennox-Gastaut syndrome patients this quarter.
With just a three-month treatment period to measure efficacy against a placebo, it won’t take too long for investors to know whether Epidolex helps epileptics.
GW Pharmaceuticals and its more than five dozen discovered cannabinoids are at the heart of a lot of important research. To me, nothing is more intriguing than the potential that marijuana might hold for treating type 2 diabetes. According to the Centers for Disease Control and Prevention, 29.1 million people in the U.S.
To read more, visit http://www.nasdaq.com/article/marijuana-could-be-the-answer-to-fighting-these-3-diseases-cm431357